A4091-10mg | PCI-34051 [950762-95-5] Biotrend

Background

PCI-34051 is a potent, specific inhibitor of histone deacetylase 8 (HDAC8) with greater than 200-fold selectivity over the other HDAC isoforms, such as 1, 2, 3, 6 and 10. It induces caspase dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines. PCI-34051 does not cause detectable histone or tubulin acetylation and also does not inhibit growth or induce apoptosis in normal cells such as PBMCs or fibroblasts. Although a phospholipase C-gamma1 (PLCgamma1) defective line is resistant, cells defective in T-cell receptor signaling are still sensitive to PCI-34051 induced apoptosis.

References:
[1]. S Balasubramanian, J Ramos, W Luo, M Sirisawad, E Verner, J J Buggy. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia (2008) 22, 1026–1034.
[2]. Sriram Balasubramanian, Erik Verner, Joseph J. Buggy. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Letters. Volume 280, Issue 2, 8 August 2009, Pages 211–221.

Product Citation

1. Yu X, Li H, et al. "Involvement of p53 acetylation in growth suppression of Cutaneous T-cell lymphomas induced by HDAC inhibition." J Invest Dermatol. 2020;S0022-202X(20)30214-1. PMID:32119867
2. Huang Y, Yang W, et al. "Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress." Cell Mol Biol Lett. 2018 Jul 28;23:34. PMID:30065760

Chemical Properties

Storage	Store at -20°C
M.Wt	296.32
Cas No.	950762-95-5
Formula	C₁₇H₁₆N₂O₃
Synonyms	PCI34051, PCI 34051
Solubility	insoluble in H2O; insoluble in EtOH; ≥14.8 mg/mL in DMSO
Chemical Name	N-hydroxy-1-[(4-methoxyphenyl)methyl]indole-6-carboxamide
SDF	Download SDF
Canonical SMILES	COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Kinase experiment [1]:
Histone deacetylase activity	For PCI-34051 characterization, measurements were perfomed in a reaction volume of 100 μL using 96-well assay plates in a fluorescence plate reader. For each isozyme, the HDAC protein in reaction buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% dimethyl sulfoxide, pH 7.4, supplemented with bovine serum albumin at concentrations of 0 ~ 0.05%) was mixed with PCI-34051 at various concentrations and allowed to incubate for 15 mins. Trypsin was added to a final concentration of 50 nM, and acetyl-Gly-Ala-(N-acetyl-Lys)-amino-4-methylcoumarin was added to a final concentration of 25 ~ 100 μM to initiate the reaction. After a 30 min lag time, the fluorescence was measured over a 30 min time frame using an excitation wavelength of 335 nm and a detection wavelength of 460 nm. The increase in fluorescence with time was used as the measure of the reaction rate.
Cell experiment [1]:
Cell lines	T-cell derived lines (Jurkat, HuT78, HSB-2 and Molt-4 cells)
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reaction Conditions	5 μM; 2 days
Applications	The HDAC8-selective inhibitor PCI-34051 was cytotoxic to T-cell derived lines.
References: [1]. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008 May;22(5):1026-34.

Biological Activity

Description	PCI-34051 is a potent and specific inhibitor of HDAC8 with an IC50 value of 10 nM.
Targets	HDAC8	HDAC6	HDAC1	HDAC10	HDAC2	HDAC3
IC50	10 nM	2.9 μM	4 μM	13 μM	>50 μM	>50 μM